Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of ...

The strategies for targeting the ANGPT–TIE system range from developing receptor tyrosine kinase inhibitors (TKIs; to target TIE2), as well as selective and non-selective traps (to target ANGPT1 ...